The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.
Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.
Learning Objectives
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data; differentiate the latest guideline updates for the treatment of T2D
- Consider comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF)
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF
- Assess the interrelationships linking diabetes, HF and CVD
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
More from this programme
Part 1
SGLT2 in HF Now and the Future
| 1 session | |
| SGLT2 in HF Now and the Future | Watch now |
Part 2
DAPA-HF Trial Design Rationale
| 1 session | |
| DAPA-HF Trial Design Rationale | Watch now |
Part 3
SGLT2 beyond diabetes
| 1 session | |
| SGLT2 beyond diabetes | Watch now |
Part 4
Guidelines, Recent Data & Future Practices
Part 5
DAPA-HF Trial
| 1 session | |
| DAPA-HF Trial | Watch now |
Part 6
Discussion with the DAPA-HF Trialist
Faculty Biographies
Andrew JS Coats
Professor of Cardiology and Scientific Director
Professor Andrew Coats was born in Melbourne, Australia. He studied at St Catherine’s College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours, and then completed his medical degree (M.B. B.Chir.) at Clare College, Cambridge. He later obtained higher doctorates (D.M. and D.Sc.) in recognition of his substantial contributions to cardiovascular medicine, and he also completed an MBA at the London Business School. Professor Coats serves as Editor-in-Chief of the Cardiac Failure Review journal.
Career Overview
Andrew Coats is an internationally renowned academic cardiologist, inventor, and university leader with a career spanning more than three decades. He is currently the Scientific Director and CEO of the Heart Research Institute in Sydney, Australia. He also serves as Dean of the Royal Australasian College of Physicians, Affiliate Professor at Deakin University, and Emeritus Professor of Medicine at Monash University.
…
Carolyn Lam
Professor and Senior Consultant Cardiologist
Prof Carolyn Lam is a Senior Consultant Cardiologist and Director of Women’s Heart Health at the National Heart Centre Singapore, where she pioneered the country’s first Women’s Heart Clinic. Internationally recognised for her expertise in heart failure with preserved ejection fraction (HFpEF), Prof Lam has played a key role in landmark clinical trials including PARAGON-HF, EMPEROR-Preserved, DELIVER and FINEARTS-HF.
Her work helped establish the first FDA-approved treatment for HFpEF and the first trial to demonstrate robust clinical benefit in this patient population. A prolific researcher, Prof Lam has authored over 700 peer-reviewed publications in top journals such as New England Journal of Medicine, Lancet, JAMA, Circulation and